Investigating harmful antibodies in a kidney disease
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
This study is looking at how certain antibodies in people with IgA nephropathy might harm their kidneys, and by understanding this better, we hope to find new ways to treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10783000 on NIH RePORTER |
What this research studies
This research focuses on IgA nephropathy (IgAN), a common kidney disease that can lead to severe health issues, including end-stage renal disease. The project aims to understand how specific autoantibodies contribute to the formation of harmful immune complexes that damage the kidneys. By analyzing the molecular characteristics of these autoantibodies, researchers hope to uncover the mechanisms behind this disease and pave the way for targeted treatments. Patients with IgAN will be central to this research, as their immune responses provide critical insights.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with IgA nephropathy, regardless of age or ethnicity.
Not a fit: Patients with kidney diseases other than IgA nephropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of specific treatments for IgA nephropathy, improving patient outcomes and quality of life.
How similar studies have performed: Previous research has shown promise in understanding autoimmune mechanisms in kidney diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Green, Todd Jason — University of Alabama at Birmingham
- Study coordinator: Green, Todd Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.